Gumokimab is an investigational immunoglobulin G1 (IgG1) monoclonal antibody targeting the interleukin-17A (IL-17A) pathway, specifically developed for the treatment of moderate-to-severe plaque psoriasis. It functions as a direct and potent inhibitor of IL-17A signaling. By binding with high affinity to the cytokine IL-17A, gumokimab prevents it from interacting with its primary receptor, IL-17 receptor A (IL-17RA), which is expressed on keratinocytes and other immune cells. This blockade inhibits the downstream pro-inflammatory cascade that drives keratinocyte hyperproliferation, neutrophil recruitment, and skin inflammation characteristic of psoriasis. Its design as an IgG1 antibody may also engage immune effector functions, potentially enhancing clearance of IL-17A complexes. Clinical data suggest this mechanism translates into faster and more effective clinical improvement in skin lesions compared to some existing therapies.